Opinion|Videos|February 23, 2024
Patient Case Presentation: A 34-Year-Old Woman with HER+ mBC and Brain Metastases
Rani Bansal, MD, discusses the case of a 54-year-old post-menopausal patient who develops liver and brain metastases after undergoing prior therapy with trastuzumab/pertuzumab and T-DM1.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
4
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
5